Fulcrum Therapeutics

Clinical trials sponsored by Fulcrum Therapeutics, explained in plain language.

Fulcrum Therapeutics FULC NASDAQ

A clinical-stage biopharmaceutical company developing small molecules for genetic diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1 Completed 1 Terminated 4

Sickle cell drug pociredir tested for Long-Term safety in 50 patients

Disease control By invitation only

This study looks at the long-term safety of the drug pociredir in 50 adults with sickle cell disease who have already taken it and seen benefits in an earlier study. Participants will take pociredir once daily for up to 48 months. The main goal is to track side effects and other …

Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 12:07 UTC

Fulcrum Therapeutics

Sickle cell drug pociredir tested for Long-Term safety in 50 patients